BDX insider buying and SEC filings, explained
Becton Dickinson & Co. · CIK 10795
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$653K
Planned sales (10b5-1)
$2.1M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 26, 2026 | Planned (10b5-1) | Michael Feld (EVP, Chief Revenue Officer) sold 76 shares at $198.13 ($15K), marked as a 10b5-1 plan trade. Holdings down <1% to 19,568 shares. | SEC filing Filed Oct 27, 2026, 2:27 PM ET |
| Sep 28, 2026 | Planned (10b5-1) | Michael Feld (EVP, Chief Revenue Officer) sold 76 shares at $183.70 ($14K), marked as a 10b5-1 plan trade. Holdings down <1% to 19,644 shares. | SEC filing Filed Sep 29, 2026 |
| Aug 26, 2026 | Planned (10b5-1) | Michael Feld (EVP, Chief Revenue Officer) sold 165 shares at $188.49 ($31K), marked as a 10b5-1 plan trade. Holdings down 1% to 19,720 shares. | SEC filing Filed Aug 27, 2026 |
| Aug 13, 2026 | Planned (10b5-1) | Thomas E Polen Jr (CEO and Director) sold 4,152 shares at $185.00 ($768K), marked as a 10b5-1 plan trade. Holdings down 4% to 110,163 shares. | SEC filing Filed Aug 14, 2026 |
| Aug 11, 2026 | Sale | Roland Goette (President / COO) sold 2,438 shares at $180.84 ($441K). Holdings down 14% to 14,856 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 12, 2026 |
| Jul 27, 2026 | Planned (10b5-1) | Michael Feld (EVP, Chief Revenue Officer) sold 75 shares at $157.13 ($12K), marked as a 10b5-1 plan trade. Holdings down <1% to 20,934 shares. | SEC filing Filed Jul 28, 2026 |
| Jun 26, 2026 | Planned (10b5-1) | Michael Feld (EVP, Chief Revenue Officer) sold 75 shares at $152.80 ($11K), marked as a 10b5-1 plan trade. Holdings down <1% to 21,009 shares. | SEC filing Filed Jun 26, 2026 |
| Jun 24, 2026 | Planned (10b5-1) | Michael David Garrison (EVP & Pres Med.Essntl&BioPharm) sold 1,100 shares at $145.66 ($160K), marked as a 10b5-1 plan trade. Holdings down 8% to 13,172 shares. | SEC filing Filed Jun 25, 2026 |
| Jun 10, 2026 | Planned (10b5-1) | Michael David Garrison (EVP & Pres Med.Essntl&BioPharm) sold 1,100 shares at $151.48 ($167K), marked as a 10b5-1 plan trade. Holdings down 7% to 14,272 shares. | SEC filing Filed Jun 11, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Thomas E Polen Jr (CEO and Director) sold 2,764 shares at about $146.35 ($405K), marked as a 10b5-1 plan trade. Holdings down 2% to 110,163 shares. | SEC filing Filed Jun 3, 2026 |
| May 26, 2026 | Planned (10b5-1) | Michael Feld (EVP, Chief Revenue Officer) sold 75 shares at $147.35 ($11K), marked as a 10b5-1 plan trade. Holdings down <1% to 21,084 shares. | SEC filing Filed May 27, 2026 |
| Apr 27, 2026 | Planned (10b5-1) | Michael Feld (EVP, Chief Revenue Officer) sold 74 shares at $151.94 ($11K), marked as a 10b5-1 plan trade. Holdings down <1% to 21,159 shares. | SEC filing Filed Apr 28, 2026 |
| Mar 26, 2026 | Planned (10b5-1) | Michael Feld (EVP, Chief Revenue Officer) sold 75 shares at $156.83 ($12K), marked as a 10b5-1 plan trade. Holdings down <1% to 21,233 shares. | SEC filing Filed Mar 27, 2026 |
| Feb 26, 2026 | Planned (10b5-1) | Michael Feld (EVP, Chief Revenue Officer) sold 75 shares at $181.84 ($14K), marked as a 10b5-1 plan trade. Holdings down <1% to 21,308 shares. | SEC filing Filed Feb 27, 2026 |
| Feb 18, 2026 | Sale | Bertram L. Scott (Director) sold 953 shares at $182.61 ($174K). Holdings down 3% to 36,763 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 18, 2026 |
| Jan 26, 2026 | Planned (10b5-1) | Michael Feld (EVP, CRO & Pres. Life Sciences) sold 75 shares at $202.73 ($15K), marked as a 10b5-1 plan trade. Holdings down <1% to 16,431 shares. | SEC filing Filed Jan 28, 2026 |
| Jan 15, 2026 | Planned (10b5-1) | Michael David Garrison (EVP & Pres Med.Essntl&BioPharm) sold 1,610 shares at about $207.46 ($334K), marked as a 10b5-1 plan trade. Holdings down 12% to 12,095 shares. | SEC filing Filed Jan 16, 2026 |
| Dec 26, 2025 | Planned (10b5-1) | Michael Feld (EVP, CRO & Pres. Life Sciences) sold 74 shares at $196.08 ($15K), marked as a 10b5-1 plan trade. Holdings down <1% to 16,506 shares. | SEC filing Filed Dec 29, 2025 |
| Dec 17, 2025 | Planned (10b5-1) | Michael David Garrison (EVP & Pres Med.Essntl&BioPharm) sold 629 shares at $196.03 ($123K), marked as a 10b5-1 plan trade. Holdings down 5% to 13,105 shares. | SEC filing Filed Dec 17, 2025 |
| Dec 1, 2025 | Planned (10b5-1) | Michael Feld (EVP, CRO & Pres. Life Sciences) sold 75 shares at $193.36 ($15K), marked as a 10b5-1 plan trade. Holdings down <1% to 16,580 shares. | SEC filing Filed Dec 2, 2025 |
| Nov 7, 2025 | Sale | Bertram L. Scott (Director) sold 217 shares at $176.58 ($38K). Holdings down 1% to 35,816 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 7, 2025 |
47 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow BDX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.